The European Commission has penalized pharmaceutical firm Alchem, concluding its involvement in a cartel manipulating active pharmaceutical ingredient (API) prices for over ten years. This closure of the antitrust investigation underscores regulatory scrutiny on anti-competitive practices in drug supply chains within the European market.